A truly global reach

January 14, 2013

As the world's number 1 injectable iron supplementation, Uniferon assists winning pig farmers in the fight against iron deficiency anaemia in literally all parts of the world.

As a company with an unrivalled focus on quality in all aspects of the process, we have long seen the positive effects of best practice strategies in numerous countries, and we are genuinely proud and excited as more and more countries are allowed access to Uniferon.

Today, Uniferon is available in all major pig producing countries in Europe, in the US, China and Russia. And latest, we have or are preparing launch of our injectable iron supplementation in as diverse markets as South Africa, the Ukraine and Poland.

In 2013, we will see the rise of new high-potential markets in countries where large-scale pig productions are present- and one of our new key areas is Latin America.

"Latin America is a truly exciting market for injectable iron with Brazil and Mexico as clear frontrunners. These countries in particular lays ground to skilled and ambitious pig productions that will benefit greatly from quality iron knowledge, and we are happy to supply them with Uniferon in the near future. We are currently finalizing agreements with local partnering companies, and we will be able to disclose more about this in the very near future" said Jens Fabricius, Vice President, Marketing & Business Operations at Pharmacosmos A/S.

As Uniferon moves one step even closer to a total global reach, we look ahead to a challenging and exciting 2013 with high optimism.

About Uniferon

Uniferon is a modern improved iron hydrogenated dextran based on a natural formula, which is approved for global use:

Uniferon is manufactured without the use of any organic solvents or cyanide, thus, avoiding trace residues of these impurities. Pharmacosmos manufactures iron dextran of high quality and unique purity for customers worldwide. Uniferon is the only injectable iron brand for piglets approved in the EU, the US and Asia.

About Pharmacosmos

Headquartered in Denmark, Pharmacosmos is a family-owned, international healthcare company with more than 50 years of innovation and leadership in iron- and carbohydrate-based treatments and solutions for human and animal use.

A research-based company, its ongoing R&D programme focuses on improving the lives of patients with iron deficiency with or without anaemia. More than 1 billion people live with iron deficiency anaemia and it is the leading cause of death for an estimated 180,000 people every year. This makes it one of the largest global health challenges of our time.

Pharmacosmos has subsidiaries in the Nordics, the UK and the US and its products are marketed in more than 80 countries across the world. Its manufacturing facilities are approved, among others, by the Danish Medicines Agency and the US FDA.